Abstract

Targeted therapies that deliver the expected anti-tumor effects while mitigating the adverse effects are taking the cancer world by storm. The need for such therapies in non-small cell lung cancer (NSCLC), where systemic cytotoxic chemotherapies still remain the backbone of management, is felt more than ever before. Runway success of immunotherapies such as Ipilimumab for melanoma has brought excitement among oncologists. Immune-based treatments are in various stages of evaluation for NSCLC as well. Immunotherapies using strategies of antigen based or cell based vaccines, and blocking immune checkpoints are of substantial interest. Meaningful clinical responses are yet to be reaped from these new treatment modalities.

Original languageEnglish (US)
Pages (from-to)39-47
Number of pages9
JournalWorld Journal of Clinical Oncology
Volume5
Issue number2
DOIs
StatePublished - May 10 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Immunotherapy
Therapeutics
Melanoma
Neoplasms
Vaccines
Antigens
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{9118b80e746d4ca1bf625b506e905b6b,
title = "Targeted immunotherapy for non-small cell lung cancer",
abstract = "Targeted therapies that deliver the expected anti-tumor effects while mitigating the adverse effects are taking the cancer world by storm. The need for such therapies in non-small cell lung cancer (NSCLC), where systemic cytotoxic chemotherapies still remain the backbone of management, is felt more than ever before. Runway success of immunotherapies such as Ipilimumab for melanoma has brought excitement among oncologists. Immune-based treatments are in various stages of evaluation for NSCLC as well. Immunotherapies using strategies of antigen based or cell based vaccines, and blocking immune checkpoints are of substantial interest. Meaningful clinical responses are yet to be reaped from these new treatment modalities.",
author = "Monali Vasekar and Xin Liu and Hong Zheng and Chandra Belani",
year = "2014",
month = "5",
day = "10",
doi = "10.5306/wjco.v5.i2.39",
language = "English (US)",
volume = "5",
pages = "39--47",
journal = "World Journal of Clinical Oncology",
issn = "2218-4333",
publisher = "Baishideng Publishing Group",
number = "2",

}

Targeted immunotherapy for non-small cell lung cancer. / Vasekar, Monali; Liu, Xin; Zheng, Hong; Belani, Chandra.

In: World Journal of Clinical Oncology, Vol. 5, No. 2, 10.05.2014, p. 39-47.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeted immunotherapy for non-small cell lung cancer

AU - Vasekar, Monali

AU - Liu, Xin

AU - Zheng, Hong

AU - Belani, Chandra

PY - 2014/5/10

Y1 - 2014/5/10

N2 - Targeted therapies that deliver the expected anti-tumor effects while mitigating the adverse effects are taking the cancer world by storm. The need for such therapies in non-small cell lung cancer (NSCLC), where systemic cytotoxic chemotherapies still remain the backbone of management, is felt more than ever before. Runway success of immunotherapies such as Ipilimumab for melanoma has brought excitement among oncologists. Immune-based treatments are in various stages of evaluation for NSCLC as well. Immunotherapies using strategies of antigen based or cell based vaccines, and blocking immune checkpoints are of substantial interest. Meaningful clinical responses are yet to be reaped from these new treatment modalities.

AB - Targeted therapies that deliver the expected anti-tumor effects while mitigating the adverse effects are taking the cancer world by storm. The need for such therapies in non-small cell lung cancer (NSCLC), where systemic cytotoxic chemotherapies still remain the backbone of management, is felt more than ever before. Runway success of immunotherapies such as Ipilimumab for melanoma has brought excitement among oncologists. Immune-based treatments are in various stages of evaluation for NSCLC as well. Immunotherapies using strategies of antigen based or cell based vaccines, and blocking immune checkpoints are of substantial interest. Meaningful clinical responses are yet to be reaped from these new treatment modalities.

UR - http://www.scopus.com/inward/record.url?scp=84922260552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922260552&partnerID=8YFLogxK

U2 - 10.5306/wjco.v5.i2.39

DO - 10.5306/wjco.v5.i2.39

M3 - Article

AN - SCOPUS:84922260552

VL - 5

SP - 39

EP - 47

JO - World Journal of Clinical Oncology

JF - World Journal of Clinical Oncology

SN - 2218-4333

IS - 2

ER -